Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment.

While stromal interactions are essential in cancer adaptation to hormonal therapies, the effects of bone stroma and androgen deprivation on cancer progression in bone are poorly understood. Here, we tissue-engineered and validated an in vitro microtissue model of osteoblastic bone metastases, and used it to study the effects of androgen deprivation in this microenvironment. The model was established by culturing primary human osteoprogenitor cells on melt electrowritten polymer scaffolds, leading to a mineralized osteoblast-derived microtissue containing, in a 3D setting, viable osteoblastic cells, osteocytic cells, and appropriate expression of osteoblast/osteocyte-derived mRNA and proteins, and mineral content. Direct co-culture of androgen receptor-dependent/independent cell lines (LNCaP, C4-2B, and PC3) led cancer cells to display functional and molecular features as observed in vivo. Co-cultured cancer cells showed increased affinity to the microtissues, as a function of their bone metastatic potential. Co-cultures led to alkaline phosphatase and collagen-I upregulation and sclerostin downregulation, consistent with the clinical marker profile of osteoblastic bone metastases. LNCaP showed a significant adaptive response under androgen deprivation in the microtissues, with the notable appearance of neuroendocrine transdifferentiation features and increased expression of related markers (dopa decarboxylase, enolase 2). Androgen deprivation affected the biology of the metastatic microenvironment with stronger upregulation of androgen receptor, alkaline phosphatase, and dopa decarboxylase, as seen in the transition towards resistance. The unique microtissues engineered here represent a substantial asset to determine the involvement of the human bone microenvironment in prostate cancer progression and response to a therapeutic context in this microenvironment. Cancer: 3D model mimics prostate cancer metastasis to bone A three-dimensional model of prostate tumor cells growing in a bone-like microenvironment offers a new platform for studying how metastatic prostate cancers respond to therapies. Dietmar Hutmacher and colleagues from the Queensland University of Technology in Brisbane, Australia, engineered a bone-like tissue environment by culturing bone progenitor cells in a fibrous polyester scaffold. The cells differentiated into bone-forming cells that produced the appropriate RNAs, proteins and minerals. The researchers then added various populations of prostate cancer cells to the constructs. Cell lines with the greatest bone metastatic potential grew best, and depriving cells of the hormone androgen led to a more aggressive disease phenotype consistent with that observed in the tumors of men with castration-resistant prostate cancer. The system offers a new way to test for relevant biomarkers and therapeutics in the laboratory. [ABSTRACT FROM AUTHOR]